Hemab Therapeutics priced an upsized IPO at $18 per share to raise gross proceeds of about $301.5 million, at the high end of its range. The company is set to begin trading on Nasdaq under ticker COAG and could receive an additional $45 million if underwriters exercise full overallotment. The offering underscores ongoing appetite for biopharma listings in 2026, particularly in hematology categories such as coagulation disorders including Glanzmann thrombasthenia and von Willebrand disease. Deal terms also add to a wider picture of increased public-market activity for smaller biotech companies seeking capital ahead of clinical milestones.